Intelligence Profile
Safety Profile
The safety evidence for cerebrolysin is limited in the provided literature, with most studies focusing on efficacy rather than comprehensive safety reporting.
Known Side Effects
The available evidence does not provide detailed information about cerebrolysin's side effect profile. One meta-analysis examining cerebrolysin as an adjunct to mechanical thrombectomy in acute ischemic stroke assessed both efficacy and safety, but specific adverse events are not detailed in the provided abstract.
Evidence limitation: The current evidence base lacks comprehensive safety data from controlled trials.
Contraindications
No specific contraindications are identified in the provided evidence.
Evidence limitation: Formal contraindication data is not available in the reviewed studies.
Drug Interactions
The provided evidence does not contain information about drug interactions with cerebrolysin.
Evidence limitation: No drug interaction studies or reports are included in the available evidence.
Special Populations
The evidence shows cerebrolysin has been studied in several clinical contexts:
- Acute ischemic stroke patients (including as adjunct to mechanical thrombectomy)
- Subacute stroke patients with motor deficits
- Traumatic brain injury patients with nonoperative lesions
- Bell's palsy patients
- Patients with COVID-19-related anosmia and ageusia
However, specific safety considerations for vulnerable populations (elderly, pregnant women, children, patients with renal/hepatic impairment) are not addressed in the available evidence.
Important Safety Notes
Several studies in the evidence list are marked as retractions, which raises questions about the reliability of some cerebrolysin research. This should be considered when evaluating the overall evidence base for this medication.
Disclaimer: This safety summary is based on limited available evidence. Healthcare providers should consult complete prescribing information and consider individual patient factors before prescribing cerebrolysin. Patients should discuss potential risks and benefits with their healthcare provider.
Evidence limitation: The safety profile presented here is incomplete due to insufficient safety-specific data in the provided evidence base.